Menu
Search
|

Menu

Close
X

BioXcel Therapeutics Inc BTAI.OQ (NASDAQ Stock Exchange Capital Market)

10.98 USD
+0.44 (+4.17%)
As of 4:00 PM EDT
Previous Close 10.54
Open 10.77
Volume 32,037
3m Avg Volume 13,115
Today’s High 10.98
Today’s Low 10.52
52 Week High 11.94
52 Week Low 2.41
Shares Outstanding (mil) 15.67
Market Capitalization (mil) 169.66
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.60 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
0
FY17
0
FY16
0
EPS (USD)
FY19
-0.460
FY18
-1.333
FY17
-0.276
FY16
-0.070
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.85
Price to Sales (TTM)
vs sector
--
7.90
Price to Book (MRQ)
vs sector
5.24
4.38
Price to Cash Flow (TTM)
vs sector
--
23.70
Total Debt to Equity (MRQ)
vs sector
0.00
17.64
LT Debt to Equity (MRQ)
vs sector
0.00
12.61
Return on Investment (TTM)
vs sector
-51.83
12.69
Return on Equity (TTM)
vs sector
-52.54
17.13

EXECUTIVE LEADERSHIP

Peter Mueller
Independent Chairman of the Board, Since 2017
Salary: --
Bonus: --
Vimal Mehta
President, Chief Executive Officer, Secretary, Director, Since 2017
Salary: $147,000.00
Bonus: --
Richard Steinhart
Chief Financial Officer, Since 2017
Salary: $30,000.00
Bonus: --
Frank Yocca
Chief Scientific Officer, Since 2017
Salary: $168,000.00
Bonus: --
Chids Mahadevan
Vice President - Finance, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

555 Long Wharf Dr
NEW HAVEN   CT   06511-6107

Phone: +1203.6438060

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company that is focused on the development of drugs for psychiatric disorders and rare cancers. The Company uses novel artificial intelligence (AI) for drug re-innovation processes of approved product candidates to identify new therapeutic indices. Its principal clinical development programs are BXCL501 and BXCL701. BXCL501 is a sublingual thin film formulation of dexmedetomidine (Dex) designed for the acute treatment of agitation resulting from neurological and psychiatric disorders. BXCL701 is an immuno-oncology agent designed for the treatment of prostate and pancreatic cancer.

SPONSORED STORIES